Breaking News Instant updates and real-time market news.

SHPG

Shire

$174.37

1.15 (0.66%)

, RHHBY

Roche

$0.00

(0.00%)

14:31
08/07/18
08/07
14:31
08/07/18
14:31

Shire denied bid to have Roche's Hemlibra pulled from market, Bloomberg says

Roche (RHHBY) can continue selling the hemophilia drug as a judge denied Shire's (SHPG) request for an injunction, according to Bloomberg.

SHPG

Shire

$174.37

1.15 (0.66%)

RHHBY

Roche

$0.00

(0.00%)

  • 08

    Aug

  • 21

    Dec

SHPG Shire
$174.37

1.15 (0.66%)

04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
RHHBY Roche
$0.00

(0.00%)

06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

NUS

Nu Skin

$66.17

0.75 (1.15%)

15:14
11/21/18
11/21
15:14
11/21/18
15:14
Recommendations
Nu Skin analyst commentary  »

Nu Skin pullback a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.38

1.08 (25.12%)

15:10
11/21/18
11/21
15:10
11/21/18
15:10
Options
Call buyers in Qudian as shares rally 24% »

Call buyers in Qudian as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

HDSN

Hudson Technologies

$1.13

0.04 (3.67%)

15:04
11/21/18
11/21
15:04
11/21/18
15:04
Options
Hudson Technologies options imply 31.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.52

0.5 (3.84%)

15:00
11/21/18
11/21
15:00
11/21/18
15:00
Options
Size Reverse/Conversion trade in Barrick Gold suggests stock replacement »

Size Reverse/Conversion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIH

Oil Services Holders Trust

$18.87

0.37 (2.00%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Options
Active trading in VanEck Vectors Oil Services 20-strike calls »

Active trading in VanEck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,529.99

34.39 (2.30%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Periodicals
NYC officials say half of Queens Amazon jobs won't be in tech, WSJ says »

New York City officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

SQM

SQM

$43.70

1.825 (4.36%)

14:49
11/21/18
11/21
14:49
11/21/18
14:49
Options
SQM options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
11/21/18
11/21
14:45
11/21/18
14:45
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.